Related Experiment Videos
Risk and management of hypertension-related left ventricular hypertrophy
1EPICORE Centre, Department of Medicine, University of Alberta, Edmonton, Canada.
Insights
Treating hypertension significantly reduces stroke and coronary heart disease (CHD) risks. Antihypertensive drugs also effectively reduce left ventricular hypertrophy (LVH), a key risk factor in hypertensive patients.
Area of Science:
- Cardiology
- Public Health
- Pharmacology
Background:
- Hypertension treatment has reduced stroke and coronary heart disease (CHD) morbidity and mortality.
- While stroke reduction is clear, CHD benefits from treatment have shown only trends in individual trials.
- Left ventricular hypertrophy (LVH) in hypertensive patients significantly increases cardiovascular and all-cause mortality risk.
Purpose of the Study:
- To evaluate the impact of hypertension treatment on cardiovascular outcomes, specifically stroke and CHD.
- To assess the role of left ventricular hypertrophy (LVH) in hypertensive patients and its response to treatment.
- To determine the effectiveness of common antihypertensive drug classes in reducing left ventricular mass.
Main Methods:
- Review of epidemiological studies and clinical trials on hypertension.
- Meta-analysis of existing data to assess CHD risk reduction.
- Analysis of data on LVH diagnosis and risk prediction using electrocardiography and echocardiography.
- Meta-analysis of clinical studies on the effect of antihypertensive drugs on left ventricular mass.
Main Results:
- Hypertension treatment convincingly reduces stroke risk.
- A meta-analysis suggests a significant, albeit smaller, reduction in CHD risk with hypertension treatment.
- LVH is a significant risk factor, and data suggest it can regress with adequate hypertension management.
- Four major antihypertensive drug classes (beta-blockers, diuretics, calcium channel antagonists, ACE inhibitors) are associated with significant reductions in left ventricular mass.
Conclusions:
- Effective hypertension management is crucial for reducing cardiovascular morbidity and mortality, including stroke and CHD.
- Left ventricular hypertrophy (LVH) is a significant risk marker in hypertension and should prompt careful patient management.
- Commonly prescribed antihypertensive medications effectively reduce left ventricular mass, contributing to improved cardiovascular health in hypertensive individuals.
Abstract:
Knowledge gained from epidemiological studies and clinical trials on hypertension has led to impressive reductions in morbidity and mortality, particularly from stroke and coronary heart disease (CHD) as complications of end-organ damage from untreated, prolonged systemic hypertension. Data on reductions in stroke when hypertension is treated have been clear and convincing from individual clinical trials. Most of these trials, however, have consistently shown only trends towards a reduction in CHD, and few have individually reported statistically significant reductions. A recent meta-analysis, however, suggests that a significant beneficial reduction in CHD exists when the overall data are examined, although at a lower magnitude of benefit and lesser degree of certainty than for stroke. The presence of left ventricular hypertrophy (LVH) increases the risk of subsequent cardiovascular disease events, cardiovascular mortality and all-cause mortality in hypertensive patients. Although echocardiography appears more sensitive than electrocardiography in diagnosing LVH, much of the information demonstrating risks from LVH is from electrocardiography data, and it is not clear how echocardiography will change the risk prediction. Some data from large clinical trials and populations studies suggest that LVH regresses, particularly if the hypertension is adequately treated. A meta-analysis of a large number of small clinical studies in hypertensive patients suggests that the 4 commonly used antihypertensive drug classes, beta-blockers, diuretics, calcium channel antagonists and ACE inhibitors, are all associated with significant reductions in left ventricular mass. While the primary indication for treatment is clearly the hypertension and not the LVH, the presence of the latter necessitates careful treatment and follow-up of these hypertensive individuals.